Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality.
“We are excited to welcome Karen and Jolly in these important roles as we continue to build the capabilities to establish Kymera as a leading, fully integrated degrader medicines company,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “Karen’s experience in driving organizational and talent strategies in dynamic R&D organizations will be instrumental in supporting our continued growth, while Jolly’s considerable experience in quality assurance for clinical and commercial-stage products will be invaluable as we continue to advance and broaden Kymera’s pipeline of novel protein degraders.”
Karen Weisbach, Vice President, People and Culture
Jolly Bhatia, Vice President, Quality
About Kymera Therapeutics
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Smart Government â€“ Digital Signage and Citizen Kiosks
Smart Buildings Beyond HVAC
Who Benefits from Network Slicing?